CY1112174T1 - Παραγωγα συντηγμενης αζολο-πυριμιδινης - Google Patents

Παραγωγα συντηγμενης αζολο-πυριμιδινης

Info

Publication number
CY1112174T1
CY1112174T1 CY20111100771T CY111100771T CY1112174T1 CY 1112174 T1 CY1112174 T1 CY 1112174T1 CY 20111100771 T CY20111100771 T CY 20111100771T CY 111100771 T CY111100771 T CY 111100771T CY 1112174 T1 CY1112174 T1 CY 1112174T1
Authority
CY
Cyprus
Prior art keywords
disease
pi3k
present
diseases
derivatives
Prior art date
Application number
CY20111100771T
Other languages
English (en)
Inventor
Toshiki Murata
Megumi Yamauchi
Tetsuo Kikuchi
Takashi Yoshino
Naoki Omori
Mami Miura
Hideki Tsujishita
Makoto Shimazaki
Klaus Dr Urbahns
Kinji Fuchikami
Satoko Matsukawa
Florian Gantner
Kevin Bacon
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of CY1112174T1 publication Critical patent/CY1112174T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αφορά νέα παράγωγα συντηγμένης αζολοπυριμιδίνης, διεργασίες για την παρασκευή τους και φαρμακευτικά παρασκευάσματα που τα περιέχουν. Τα παράγωγα συντηγμένης αζολοπυριμιδίνης της παρούσας εφεύρεσης επιδεικνύουν ενισχυμένη δραστικότητα για την αναστολή φωσφοτιδυλινοσιτόλης-3-κινάσης (ΡI3K), ιδιαίτερα για την αναστολή της ΡΙ3Κ-γ και μπορούν να χρησιμοποιηθούν για την προφύλαξη και θεραπεία ασθενειών που σχετίζονται με την ΡI3K και συγκεκριμένα με τη δραστικότητα της ΡI3Κ-γ. Ειδικότερα, τα παράγωγα αζολίου της παρούσας εφεύρεσης είναι χρήσιμα για τη θεραπεία και προφύλαξη ασθενειών ως εξής: φλεγμονωδών και ανοσορρυθμιστικών διαταραχών, όπως άσθματος, ατοπικής δερματίτιδας, ρινίτιδας, αλλεργικών ασθενειών, χρόνιας αποφρακτικής πνευμονοπάθειας (ΧΑΠ), σηπτικού σοκ, ασθενειών των αρθρώσεων, αυτοάνοσων παθολογιών όπως ρευματοειδούς αρθρίτιδας, και νόσου του Graves, καρκίνου, διαταραχών μυοκαρδιακής συσταλτικότητας, καρδιακής ανεπάρκειας, θρομβοεμβολισμού, ισχαιμίας, και αθηροσκλήρωσης. Οι ενώσεις της παρούσας εφεύρεσης είναι επίσης χρήσιμες για πνευμονική υπέρταση, νεφρική ανεπάρκεια, καρδιακή υπερτροφία, καθώς επίσης νευροεκφυλιστικές διαταραχές όπως νόσο Parkinson, νόσο Alzheimer, διαβήτη και εστιακή ισχαιμία, εφόσον οι ασθένειες αφορούν επίσης τη δραστικότητα της ΡI3Κ σε ένα υποκείμενο άνθρωπο ή ζώο.
CY20111100771T 2002-09-30 2011-08-10 Παραγωγα συντηγμενης αζολο-πυριμιδινης CY1112174T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30
EP08075839A EP2042504B1 (en) 2002-09-30 2003-09-18 Fused azole-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
CY1112174T1 true CY1112174T1 (el) 2015-12-09

Family

ID=32039115

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100017T CY1109790T1 (el) 2002-09-30 2009-01-09 Παραγωγα συντηγμενου αζολιου-πυριμιδινης
CY20111100771T CY1112174T1 (el) 2002-09-30 2011-08-10 Παραγωγα συντηγμενης αζολο-πυριμιδινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20091100017T CY1109790T1 (el) 2002-09-30 2009-01-09 Παραγωγα συντηγμενου αζολιου-πυριμιδινης

Country Status (33)

Country Link
US (2) US7511041B2 (el)
EP (2) EP1549652B1 (el)
JP (1) JP4790266B2 (el)
KR (1) KR101059652B1 (el)
CN (1) CN100384846C (el)
AR (2) AR041426A1 (el)
AT (2) ATE411996T1 (el)
AU (1) AU2003293310B2 (el)
BR (1) BRPI0314830B8 (el)
CA (1) CA2499134C (el)
CY (2) CY1109790T1 (el)
DE (1) DE60324296D1 (el)
DK (2) DK2042504T3 (el)
EC (2) ECSP055768A (el)
ES (2) ES2312843T3 (el)
HK (1) HK1084393A1 (el)
HR (2) HRP20050375B1 (el)
IL (1) IL166855A (el)
MA (1) MA27483A1 (el)
MX (1) MXPA05001808A (el)
MY (1) MY140756A (el)
NO (1) NO331457B1 (el)
NZ (1) NZ539062A (el)
PE (1) PE20050089A1 (el)
PL (1) PL226562B1 (el)
PT (2) PT1549652E (el)
RU (1) RU2326881C9 (el)
SI (2) SI1549652T1 (el)
TW (1) TWI327570B (el)
UA (1) UA82205C2 (el)
UY (1) UY28001A1 (el)
WO (1) WO2004029055A1 (el)
ZA (1) ZA200503306B (el)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN102718665B (zh) 2003-08-29 2015-09-16 三井化学株式会社 农园艺用杀虫剂的制备中间体
DK1761540T3 (en) 2004-05-13 2016-11-21 Icos Corp Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA
MX2007004051A (es) 2004-10-07 2007-05-24 Boehringer Ingelheim Int Pi3-quinasas.
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP2360278A1 (en) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnostic for lung disorders using class prediction
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
KR101422301B1 (ko) * 2006-04-26 2014-07-30 에프. 호프만-라 로슈 아게 약학적 화합물
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (en) 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
JP2010539239A (ja) * 2007-09-17 2010-12-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
WO2009039457A1 (en) 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
WO2009111547A1 (en) * 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2009128520A1 (ja) * 2008-04-18 2009-10-22 塩野義製薬株式会社 Ｐ１３ｋ阻害活性を有する複素環化合物
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US8791131B2 (en) * 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
EP2364983B1 (en) * 2008-11-11 2013-10-23 Jeil Pharmaceutical Co., Ltd. Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
PT2355828T (pt) 2008-11-13 2018-07-02 Gilead Calistoga Llc Terapias para malignidades hematológicas
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
CA2750935A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
ES2548253T3 (es) 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
CA2759476C (en) * 2009-04-30 2018-10-09 Julie Nicole Hamblin Novel compounds
WO2011011550A1 (en) 2009-07-21 2011-01-27 Calistoga Pharmaceuticals Inc. Treatment of liver disorders with pi3k inhibitors
CA2773848A1 (en) * 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2621486A1 (en) 2010-10-01 2013-08-07 Bayer Intellectual Property GmbH Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
EP2638044B1 (en) 2010-11-11 2017-08-30 Bayer Intellectual Property GmbH Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2638043B1 (en) * 2010-11-11 2017-06-07 Bayer Intellectual Property GmbH Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
KR20140133590A (ko) 2012-03-05 2014-11-19 길리아드 칼리스토가 엘엘씨 (s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태
EP3626308A1 (en) 2013-03-14 2020-03-25 Veracyte, Inc. Methods for evaluating copd status
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
CA2908776C (en) 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
CN110003178B (zh) 2013-05-01 2022-02-25 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
NZ736970A (en) 2013-12-20 2018-11-30 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN108884098B (zh) * 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CA3045041A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
EP3585437B1 (en) 2017-02-24 2022-12-21 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
CU24607B1 (es) 2017-09-08 2022-06-06 Bayer Consumer Care Ag Sólido estable, liofilizado, que contiene copanlisib, útil para dilución y aplicaciones terapéuticas
MX2020003126A (es) * 2017-09-20 2020-10-01 Abm Therapeutics Corp Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
WO2020020385A1 (zh) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
CA3110754A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
CA3116230A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236A (zh) * 2022-04-25 2022-06-14 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
RU2203669C2 (ru) 1994-08-12 2003-05-10 Про-Нейрон Инк. Способы лечения сепсиса и воспалений с помощью оксипуриновых нуклеозидов
AU709190B2 (en) * 1996-01-29 1999-08-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
SI2223922T1 (sl) 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
CN100345830C (zh) * 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物

Also Published As

Publication number Publication date
KR20050067404A (ko) 2005-07-01
MA27483A1 (fr) 2005-08-01
RU2005113165A (ru) 2005-10-10
ATE411996T1 (de) 2008-11-15
IL166855A (en) 2014-05-28
AU2003293310B2 (en) 2010-04-01
AR041426A1 (es) 2005-05-18
US20060128732A1 (en) 2006-06-15
EP2042504B1 (en) 2011-06-01
ES2312843T3 (es) 2009-03-01
EP2042504A1 (en) 2009-04-01
US20090270388A1 (en) 2009-10-29
DK2042504T3 (da) 2011-09-19
PE20050089A1 (es) 2005-04-20
ECSP055768A (es) 2005-08-11
DK1549652T3 (da) 2009-02-23
HRP20050375A2 (en) 2006-05-31
RU2326881C2 (ru) 2008-06-20
WO2004029055A1 (en) 2004-04-08
ES2367141T3 (es) 2011-10-28
KR101059652B1 (ko) 2011-08-25
BRPI0314830B1 (pt) 2018-03-27
US7511041B2 (en) 2009-03-31
SI2042504T1 (sl) 2011-10-28
UA82205C2 (en) 2008-03-25
PL375935A1 (en) 2005-12-12
NO20052076L (no) 2005-04-27
NO331457B1 (no) 2012-01-09
TW200413379A (en) 2004-08-01
CY1109790T1 (el) 2014-09-10
RU2326881C9 (ru) 2009-04-10
ATE511510T1 (de) 2011-06-15
ZA200503306B (en) 2006-07-26
CA2499134A1 (en) 2004-04-08
EP1549652A1 (en) 2005-07-06
HK1084393A1 (en) 2006-07-28
UY28001A1 (es) 2004-04-30
TWI327570B (en) 2010-07-21
HRP20131159A2 (hr) 2014-05-23
DE60324296D1 (de) 2008-12-04
JP2006508063A (ja) 2006-03-09
SI1549652T1 (sl) 2009-04-30
JP4790266B2 (ja) 2011-10-12
PL226562B1 (pl) 2017-08-31
PT1549652E (pt) 2008-12-15
MY140756A (en) 2010-01-15
HRP20050375B1 (hr) 2014-03-14
PT2042504E (pt) 2011-09-07
NZ539062A (en) 2007-05-31
HRP20131159B1 (hr) 2019-11-01
MXPA05001808A (es) 2005-08-16
BR0314830A (pt) 2005-08-16
AU2003293310A1 (en) 2004-04-19
CN100384846C (zh) 2008-04-30
CN1688582A (zh) 2005-10-26
US8129386B2 (en) 2012-03-06
BRPI0314830B8 (pt) 2021-05-25
ECSP11005768A (es) 2011-03-31
CA2499134C (en) 2011-12-20
EP1549652B1 (en) 2008-10-22
AR072458A2 (es) 2010-09-01

Similar Documents

Publication Publication Date Title
CY1112174T1 (el) Παραγωγα συντηγμενης αζολο-πυριμιδινης
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
CY1106748T1 (el) Ν-(3,3-dimethylindolin-6-yl){2-[(4-pyridylmethyl) amino}(3-pyridyl)}carboxamide και φαρμακευτικες συνθεσεις της
CY1111316T1 (el) Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
DE602004015810D1 (de) Substituierte isochinolinderivate und anwendungsverfahren
CY1108746T1 (el) Παραγωγα 2-φαινοξυ- και 2-φαινυλοσουλφοναμιδιου με ανταγωνιστικη δραστικοτητα ccr3 για την θεραπεια του ασθματος και αλλων φλεγμονωδων ή ανοσολογικων διαταραχων
CY1112571T1 (el) 2,4-πυριμιδινοδιαμινες χρησιμες στην αντιμετωπιση νεοπλασματικων νοσων, φλεγμονωδων διαταραχων και διαταραχων του ανοσοποιητικου συστηματος
CY1112708T1 (el) [1η-ινδολο-5-υλο)-ετεροαρυλοξυ]-(1-αζα-δικυκλο[3.3.1]εννεανια ως χολινεργικοι συνδετες του ν-achr για την θεραπεια των ψυχωτικων και νευροεκφυλιστικων διαταραχων
CY1109348T1 (el) Διυδρο-θειενο-πυριμιδινες για τη θεραπεια φλεγμονωδων παθησεων
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
EA200200249A1 (ru) Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов
CY1108094T1 (el) Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης
CY1114517T1 (el) Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
EA200700116A1 (ru) Четвертичные соли, антагонисты ccr2
DE60141895D1 (de) Substituierte beta-carboline mit ikb-kinase hemmender wirkung
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
ECSP055844A (es) Nuevos compuestos triciclicos
CY1109076T1 (el) Παραγωγα της 4- phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για θεραπεια της στειροτητας
JP6017496B2 (ja) 新規ヘテロ環化合物およびその使用
DE50310080D1 (de) 3-SUBSTITUIERTE 3,4-DIHYDRO-THIENOi2,3-D PYRIMIDIN-4-ONE-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG
EP1412028B1 (en) Tetrahydroindolone derivatives linked to arylpiperazines